JPWO2023022912A5 - - Google Patents

Info

Publication number
JPWO2023022912A5
JPWO2023022912A5 JP2024508654A JP2024508654A JPWO2023022912A5 JP WO2023022912 A5 JPWO2023022912 A5 JP WO2023022912A5 JP 2024508654 A JP2024508654 A JP 2024508654A JP 2024508654 A JP2024508654 A JP 2024508654A JP WO2023022912 A5 JPWO2023022912 A5 JP WO2023022912A5
Authority
JP
Japan
Prior art keywords
theta
crystalline form
diabetes
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534014A (ja
JP2024534014A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039941 external-priority patent/WO2023022912A1/en
Publication of JP2024534014A publication Critical patent/JP2024534014A/ja
Publication of JPWO2023022912A5 publication Critical patent/JPWO2023022912A5/ja
Publication of JP2024534014A5 publication Critical patent/JP2024534014A5/ja
Pending legal-status Critical Current

Links

JP2024508654A 2021-08-20 2022-08-10 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態 Pending JP2024534014A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163235662P 2021-08-20 2021-08-20
US63/235,662 2021-08-20
US202163279053P 2021-11-12 2021-11-12
US63/279,053 2021-11-12
US202263310076P 2022-02-14 2022-02-14
US63/310,076 2022-02-14
PCT/US2022/039941 WO2023022912A1 (en) 2021-08-20 2022-08-10 Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2024534014A JP2024534014A (ja) 2024-09-18
JPWO2023022912A5 true JPWO2023022912A5 (https=) 2025-08-19
JP2024534014A5 JP2024534014A5 (https=) 2025-08-19

Family

ID=83192065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508654A Pending JP2024534014A (ja) 2021-08-20 2022-08-10 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態

Country Status (16)

Country Link
US (2) US12018032B2 (https=)
EP (1) EP4387972A1 (https=)
JP (1) JP2024534014A (https=)
KR (1) KR20240087693A (https=)
CN (1) CN119816500A (https=)
AU (1) AU2022331496A1 (https=)
CA (1) CA3229150A1 (https=)
CL (1) CL2024000520A1 (https=)
CO (1) CO2024002671A2 (https=)
IL (1) IL310717A (https=)
JO (1) JOP20240031A1 (https=)
MX (1) MX2024002189A (https=)
PE (1) PE20241728A1 (https=)
TW (1) TW202313004A (https=)
WO (1) WO2023022912A1 (https=)
ZA (1) ZA202401605B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
US20250353854A1 (en) * 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2024249950A1 (en) * 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025110175A1 (ja) * 2023-11-21 2025-05-30 学校法人慈恵大学 真珠腫治療薬

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
JP3498456B2 (ja) 1995-12-11 2004-02-16 Ｊｓｒ株式会社 液晶表示素子
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR20020060160A (ko) 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
IL154016A0 (en) 2000-08-31 2003-07-31 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
MXPA06004657A (es) 2003-10-28 2006-06-27 Pharmacia Corp Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102004048877A1 (de) 2004-10-07 2006-04-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg PI3-Kinasen
KR20070064660A (ko) 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ｐｉ３ 키나제
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
EP1955077B1 (en) 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
MX2008010187A (es) 2006-02-10 2008-10-31 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
MX2011000834A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolopiridin cinasa.
US8486936B2 (en) 2009-05-05 2013-07-16 AllaChem, LLC Antagonist of smoothened
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
BR112013025142A2 (pt) 2011-04-01 2019-09-24 Univ Utah Res Found análogos de 3-(1h-benzo{d}imidazol-2-il)-1h-indazol substituído como inibidores da cinase pdk1
JP2014166961A (ja) 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd 新規インダゾール誘導体
CN102266341A (zh) 2011-06-20 2011-12-07 广州市第十二人民医院 嗓唑并嘧啶类化合物在制备治疗肺癌药物中的应用
US9745304B2 (en) 2013-01-30 2017-08-29 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as MKNK-1 kinase inhibitors
KR20140125117A (ko) 2013-04-18 2014-10-28 한국화학연구원 카르바닐리드 유도체를 유효성분으로 포함하는 이상증식혈관 질환의 예방 또는 치료용 조성물
WO2015000959A1 (en) 2013-07-03 2015-01-08 Norwegian University Of Science And Technology (Ntnu) 4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
JP2015183128A (ja) 2014-03-25 2015-10-22 東洋インキＳｃホールディングス株式会社 波長変換性樹脂組成物及び太陽電池封止材
EP2924039A1 (en) 2014-03-27 2015-09-30 Universität Zürich 2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
GB201417561D0 (en) 2014-10-03 2014-11-19 Redx Pharma Ltd Compounds
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
WO2016148114A1 (ja) 2015-03-13 2016-09-22 国立大学法人北海道大学 酸化ストレス誘導神経細胞死抑制化合物
US10787444B2 (en) 2015-06-05 2020-09-29 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2017075367A1 (en) 2015-10-28 2017-05-04 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
CN107176951A (zh) 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017161280A1 (en) 2016-03-18 2017-09-21 Kyocera Corporation System and method for dual-coding for dual-hops channels
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
CN105997965B (zh) 2016-05-25 2018-05-08 山东大学 小分子化合物作为佐剂在制备抗真菌药物中的应用
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
US11247970B2 (en) 2017-03-22 2022-02-15 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
CA3092625A1 (en) 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses thereof
CN108727295B (zh) 2018-06-21 2022-04-01 济南大学 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT

Similar Documents

Publication Publication Date Title
CN112839715B (zh) 抑制shp2活性化合物的制造方法
JP4138886B2 (ja) ２−アミノ−４−（４−フルオルベンジルアミノ）−１−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法
US20080275009A1 (en) Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
CN113735834B (zh) 普那布林组合物
JPWO2023022912A5 (https=)
JP4456079B2 (ja) ｛６，７−ビス（２−メトキシ−エトキシ）−キナゾリン−４−イル｝−（３ｅ）の多形体
TWI693220B (zh) １,３,４-噻二唑化合物及其用於治療癌症之用途
US20090093495A1 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JP7112755B2 (ja) Ｊａｋ酵素阻害剤及びその製造方法と用途
KR102886764B1 (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
CN116456979A (zh) 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物
CN115916750A (zh) 用于制备具有经取代的苯基或吡啶基部分的serd三环化合物的方法
JP2025102940A5 (https=)
JPWO2021150723A5 (https=)
JPWO2020051538A5 (https=)
CN101531657A (zh) 噻唑烷二酮类药物的二甲双胍盐及其制备方法和用途
JP2026509088A (ja) 医薬化合物の塩
JP2025531538A (ja) イナボグリフロジンの新規な共結晶
WO2003045953A1 (en) Crystals of taxane derivative and process for their production
JPWO2020038983A5 (https=)
CN1249750A (zh) (e)－4,6－二氯－3－(2－氧代－1－苯基吡咯烷－3－亚基甲基)－1h－吲哚－2－甲酸的结晶水合钠盐)
JP4267447B2 (ja) 細胞増殖抑制作用を有するランタン化合物
AU3533999A (en) Phosphonic acid diester derivatives